Erythromycin increases the maximum
plasma level and AUC of
cilostazol by 47% and 73%, respectively. Other
macrolides may also interact, although it seems unlikely that they all will, see
macrolides.
In view of these effects the US manufacturers suggest halving the dose of
cilostazol in the presence of CYP3A4 inhibitors such as
erythromycin. However, the UK manufacturers contraindicate CYP3A4 inhibitors, and they specifically name
erythromycin.